|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/565 | (2006.01) |
| A61P 35/00 | (2006.01) | ||
| A61K 47/14 | (2017.01) | ||
| A61K 47/44 | (2017.01) | ||
| A61K 9/08 | (2006.01) |
| (11) | Number of the document | 2286818 |
| (13) | Kind of document | T |
| (96) | European patent application number | 10180661.0 |
| Date of filing the European patent application | 2001-01-08 | |
| (97) | Date of publication of the European application | 2011-02-23 |
| (45) | Date of publication and mention of the grant of the patent | 2020-03-18 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 0000313 | 2000-01-10 | GB | |
| 0008837 | 2000-04-12 | GB |
| (72) |
Evans, John, GB
Grundy, Rosalind, Ursula, GB
|
| (73) |
AstraZeneca AB,
151 85 Södertälje,
SE
|
| (54) | Fulvestrant formulation |
| Fulvestrant formulation |